Before And After Measurements Using Laser Profilometry Prove Wrinkle
NEW YORK, Nov. 5 /PRNewswire/ -- DermaPlus, Inc., makers of DermaLastyl anti-aging skin creams, announced today the preliminary results of their 12-week clinical trial on the anti-aging effects of its skin creams. Renowned, anti-aging doctor, Dr. Steven Lamm, oversaw the study, in which 35 volunteers were imaged by a sophisticated technique called laser profilometry before and after using DermaLastyl for 12 weeks. The profilometry data and digital photographs were analyzed by computers to compare a series of parameters such as roughness, length and depth of wrinkles. The study results showed significant improvements in all parameters: 83% of the participants showed significant improvement in skin smoothness and reduction in the appearance of fines lines and wrinkles. (Study results provided upon request.)
The key ingredient in DermaLastyl products is Elastatropin, a synthetic form of natural elastin. Elastin, the second most abundant protein in the body, is responsible for the elasticity of skin and organs, and its degradation is a well-known irreversible cause of wrinkles. DermaLastyl is revolutionary because it is the first cosmetic product ever to contain a complete functional human protein. DermaPlus synthesized the human Tropoelastin gene and uses this DNA to laboratory manufacture its own Elastatropin brand of human elastin. The study now provides unequivocal proof that topical application of DermaLastyl reduces the appearance of current wrinkles, and helps prevent the formation of new ones.
Noted microbiologist Dr. Burt Ensley, CEO of DermaPlus, Inc., said:
"After introducing our products, we were challenged in news reports by Dr.
Amy Neuberger and Dr. Lamm to provide objective evidence to support our
claims, especially since most skin cream vendors advertise the results of
consumer self-evaluation studies that are co
|SOURCE DermaPlus, Inc.|
Copyright©2007 PR Newswire.
All rights reserved